 Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator AramcholTM, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Companys scientific and clinical development programs and reports financial results for the three and six months ended June 30, 2020. The Company will host a conference call and webcast at 08:30 ET today. 